Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
B001
i
Other names:
B001, B-001
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Shanghai Pharma
Drug class:
CD20 inhibitor
Related drugs:
‹
rituximab (174)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
ublituximab-xiiy (7)
rituximab-pvvr (6)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
mosunetuzumab-axgb (2)
rituximab-arrx (2)
IMM0306 (2)
IGM-2323 (2)
AR160 (2)
glofitamab-gxbm (1)
TQB2303 (rituximab biosimilar) (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
ACTR087 (0)
ALETA-001 (0)
AcellBia (rituximab biosimilar) (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
BAT4306F (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CM355 (0)
CMG1A46 (0)
DI Leu16 IL-2 (0)
(0)
GB241 (rituximab biosimilar) (0)
GB261 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
Reditux (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MIL62 (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
ocrelizumab (0)
PRO131921 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
IGN002 (0)
AME-133v (0)
XmAb13676 (0)
TG20 (rituximab biosimilar) (0)
rituximab (174)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
ublituximab-xiiy (7)
rituximab-pvvr (6)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
mosunetuzumab-axgb (2)
rituximab-arrx (2)
IMM0306 (2)
IGM-2323 (2)
AR160 (2)
glofitamab-gxbm (1)
TQB2303 (rituximab biosimilar) (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
ACTR087 (0)
ALETA-001 (0)
AcellBia (rituximab biosimilar) (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
BAT4306F (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CM355 (0)
CMG1A46 (0)
DI Leu16 IL-2 (0)
(0)
GB241 (rituximab biosimilar) (0)
GB261 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
Reditux (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MIL62 (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
ocrelizumab (0)
PRO131921 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
IGN002 (0)
AME-133v (0)
XmAb13676 (0)
TG20 (rituximab biosimilar) (0)
›
Associations
News
Trials
Filter by
Latest
6ms
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) (clinicaltrials.gov)
P2/3, N=132, Not yet recruiting, Shanghai Jiaolian Drug Research and Development Co., Ltd
6 months ago
New P2/3 trial
|
B001
6ms
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) (clinicaltrials.gov)
P1, N=45, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial primary completion date: Apr 2024 --> Dec 2024
6 months ago
Trial primary completion date
|
B001
11ms
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) (clinicaltrials.gov)
P1, N=45, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
11 months ago
Trial completion date • Trial primary completion date
|
B001
almost3years
B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma (clinicaltrials.gov)
P1, N=30, Completed, Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting --> Completed
almost 3 years ago
Clinical • Trial completion
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
B001
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login